Pharsight

Bayer Healthcare patents expiration

1. Aliqopa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7511041 BAYER HEALTHCARE Fused azole-pyrimidine derivatives
May, 2024

(a month ago)

USRE46856 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
Oct, 2029

(5 years from now)

US8466283 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
Oct, 2029

(5 years from now)

US10383876 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
Mar, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636344 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts
Mar, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-155) Sep 14, 2024
Orphan Drug Exclusivity(ODE) Sep 14, 2024
New Chemical Entity Exclusivity(NCE) Sep 14, 2022

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

NCE-1 date: 14 September, 2021

Market Authorisation Date: 14 September, 2017

Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ALIQOPA family patents

Family Patents

2. Nubeqa patents expiration

NUBEQA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11046713 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(6 years from now)

US9657003 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(6 years from now)

US10711013 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(6 years from now)

US8975254 BAYER HEALTHCARE Androgen receptor modulating compounds
Mar, 2033

(8 years from now)

US10010530 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(11 years from now)

US10383853 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(11 years from now)

US11168058 BAYER HEALTHCARE Manufacture of a crystalline pharmaceutical product
Feb, 2038

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835515 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 30, 2024
New Indication(I-900) Aug 05, 2025

Drugs and Companies using DAROLUTAMIDE ingredient

NCE-1 date: 31 July, 2023

Market Authorisation Date: 30 July, 2019

Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage

NUBEQA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Vitrakvi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9127013 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(5 years from now)

US8513263 BAYER HEALTHCARE Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
Dec, 2029

(5 years from now)

US10172861 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(11 years from now)

US10799505 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Aug, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10047097 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(5 years from now)

US8865698 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Oct, 2029

(5 years from now)

US10005783 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(5 years from now)

US9447104 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Oct, 2029

(5 years from now)

US9676783 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Oct, 2029

(5 years from now)

US10774085 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Oct, 2029

(5 years from now)

US9782414 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(11 years from now)

US10137127 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Apr, 2037

(12 years from now)

US11191766 BAYER HEALTHCARE Methods of treating pediatric cancers
Apr, 2037

(12 years from now)

US10668072 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Apr, 2037

(12 years from now)

US11484535 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Apr, 2037

(12 years from now)

US10045991 BAYER HEALTHCARE Methods of treating pediatric cancers
Apr, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-215) Nov 26, 2025
Orphan Drug Exclusivity(ODE-220) Nov 26, 2025
Orphan Drug Exclusivity(ODE-221) Nov 26, 2025
New Chemical Entity Exclusivity(NCE) Nov 26, 2023

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

NCE-1 date: 26 November, 2022

Market Authorisation Date: 26 November, 2018

Treatment: Method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection; Method of treating cancerous solid tumors; Method of treating neuroblastoma, glioma, thyroid, and breast canc...

Dosage: SOLUTION;ORAL

More Information on Dosage

VITRAKVI family patents

Family Patents